Loading patent…
AssigneeIcahn School of Medicine at Mount Sinai
InventorsPeter Palese, Adolfo Garcia-Sastre
Estimating the term…
The present invention provides chimeric negative-stand RNA viruses that allow a subject, e.g., an avian, to be immunized against two infectious agents by using a single chimeric virus of the invention. In particular, the present invention provides chimeric influenza viruses engineered to express and incorporate into their virions a fusion protein comprising an ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an influenza virus protein. Such chimeric viruses induce an immune response against influenza virus and the infectious agent. The present invention also provides chimeric Newcastle Disease viruses (NDV) engineered to express and incorporate into their virions a fusion protein comprising the ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an NDV protein. Such chimeric viruses induce an immune response against NDV and the infectious agent.
A chimeric Newcastle Disease Virus (NDV), comprising a packaged genome comprising a nucleotide sequence encoding an F-fusion protein, wherein the F-fusion protein comprises the transmembrane and cytoplasmic domains of an NDV F protein and at least one epitope of an ectodomain of a protective antigen of an infectious agent other than NDV or an antigen associated with a disease that is anchored by the C-terminus of the antigen, so that the F-fusion protein is expressed and incorporated into the chimeric NDV, and wherein the antigen is not a paramyxovirus antigen.
A chimeric Newcastle Disease Virus (NDV), comprising a packaged genome comprising a nucleotide sequence encoding an HN-fusion protein, wherein the HN-fusion protein comprises the transmembrane and cytoplasmic domains of an NDV HN protein and at least one epitope of an ectodomain of a protective antigen of an infectious agent other than NDV or an antigen associated with a disease that is anchored by the N-terminus of the antigen, so that the HN protein-fusion protein is expressed and incorporated into the chimeric NDV, and wherein the antigen is not a paramyxovirus antigen.
A chimeric Newcastle Disease Virus (NDV), comprising a packaged genome comprising a nucleotide sequence encoding an NDV F-fusion protein, wherein the F-fusion protein comprises the transmembrane and cytoplasmic domains of an NDV F protein and an ectodomain of a hemagglutinin antigen of an influenza virus that is anchored by the C-terminus of the antigen, so that the F-fusion protein is expressed and incorporated into the chimeric NDV.
A chimeric Newcastle Disease Virus (NDV), comprising a packaged genome comprising a nucleotide sequence encoding an HN-fusion protein, wherein the HN-fusion protein comprises the transmembrane and cytoplasmic domains of an NDV HN protein and an ectodomain of a neuraminidase antigen of an influenza virus that is anchored by the N-terminus, so that the HN-fusion protein is expressed and incorporated into the chimeric NDV.
A chimeric Newcastle Disease Virus (NDV), comprising a packaged genome comprising a nucleotide sequence encoding an NDV F-fusion protein, wherein the F-fusion protein comprises the transmembrane and cytoplasmic domains of an NDV F protein and an ectodomain of a hemagglutinin antigen of an influenza virus that is anchored by the C-terminus of the antigen, so that the F-fusion protein is expressed and incorporated into the chimeric NDV, wherein the F-fusion protein contains a fragment of the ectodomain of the F protein that does not retain the activity of the ectodomain of the F protein, and wherein the fragment of the ectodomain of the F protein is between 1 and 15 residues of the ectodomain of an F protein that are immediately adjacent to the transmembrane domain of the F protein.
Dependencies are inferred from the claim text.